ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1834

Effect of Hydroxychloroquine in Patients with IgA Nephropathy with Insufficient Responses to Immunosuppressive Therapy: A Retrospective Case-Control Study

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Tang, Chen, Peking University First Hospital, Beijing, Beijing, China
  • Lv, Jicheng, Peking University First Hospital, Beijing, Beijing, China
  • Shi, Sufang, Peking University First Hospital, Beijing, Beijing, China
  • Chen, Yuqing, Peking University First Hospital, Beijing, Beijing, China
  • Liu, Lijun, Peking University First Hospital, Beijing, Beijing, China
  • Zhang, Hong, Peking University First Hospital, Beijing, Beijing, China
Background

Hydroxychloroquine, a well-known immunomodulator, has recently been used in IgA nephropathy (IgAN) due to its antiproteinuric effects. We aimed to verify the effect of HCQ in patients with IgAN whose proteinuria remained above 1 g/d after conventional immunosuppressive (IS) therapy

Methods

This was a retrospective case-control study. Twenty-six patients with IgAN who received HCQ and had insufficient responses to IS therapy (corticosteroid (CS) therapy with/without IS agents) were included. 26 matched historical controls who received conventional IS therapy were selected by propensity score matching. The clinical data from 6 months were compared

Results

Proteinuria at baseline was comparable between the “IS therapy plus HCQ” and “conventional IS therapy” groups (2.35 [interquartile range (IQR), 1.47, 2.98] vs. 2.35 [IQR, 1.54, 2.98] g/d, p=0.920). There was a significant reduction in proteinuria in patients with IgAN with HCQ treatment (2.35 [IQR, 1.47, 2.98] vs. 1.10 [IQR, 0.85, 1.61] g/d, p=0.002). The percent reduction in proteinuria at 6 months was similar between the two groups (-39.81% [-66.26, -12.37] vs. -31.99% [-67.08, -9.14], p = 0.968). The cumulative frequency of patients with a 50% reduction in proteinuria during the study was also comparable between the two groups (53.8% vs. 57.7%, p= 0.780). No serious adverse events were observed during the study

Conclusion

HCQ could further reduce proteinuria in patients with IgAN who had insufficient responses to conventional IS therapy

Proteinuria of enrolled patients
 IS therapy plus HCQ
N=26
Conventional IS therapy
N=26
P-value
Proteinuria level before IS therapy (g/d)2.52(1.66,5.60)2.27(1.54,4.36)0.727
Baseline Proteinuria (g/d)2.35(1.47,2.98)2.35(1.54,2.98)0.920
Proteinuria at months 6(g/d)1.10(0.85,1.61)1.24(0.87,2.58)0.312

Proteinuria of patients during the follow-up. The dots represent the median value, the bars represent the 25th and 75th percentiles.Each Month's was compared with “Baseline” respectively. * p < 0.05; ** p < 0.01; *** p < 0.001